Click the title above for a link to open the Pharmaceutical Commerce June 2021 issue in an interactive PDF format.
FDA Approves Actemra Biosimilar
January 31st 2025Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19—in the same dosages and formulations as its tocilizumab reference product.